Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2

Journal of Cell Science

Volumn 122, Issue 18, 2009, Pages 3385-3392

  Sinha, Sutapa ^a   Vohra, Pawan Kumar ^a   Bhattacharya, Resham ^a   Dutta, Shamit ^a   Sinha, Shirshendu ^a   Mukhopadhyay, Debabrata ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Angiogenesis; Dopamine; Dopamine D2 receptor (D2DR); Migration; Phosphorylation; SHP 2; Vascular endothelial growth factor receptor 2 (VEGFR 2)

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; PHOSPHATASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; TYROSINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REGULATORY MECHANISM;

CELL MEMBRANE; CELL MOVEMENT; DOPAMINE; ENDOTHELIAL CELLS; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOPRECIPITATION; MODELS, BIOLOGICAL; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS C-FYN; PROTO-ONCOGENE PROTEINS PP60(C-SRC); PYRAZOLES; PYRIMIDINES; QUINPIROLE; RECEPTORS, DOPAMINE D2; SUBCELLULAR FRACTIONS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 70350399361     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.053124     Document Type: Article

References (45)

1. Basu, S. and Dasgupta, P. S. (2000). Role of dopamine in malignant tumor growth. Endocrine 12, 237-241.
2. Basu, S., Nagy, J. A., Pal, S., Vasile, E., Eckelhoefer, I. A., Bliss, V. S., Manseau, E. J., Dasgupta, P. S., Dvorak, H. F. and Mukhopadhyay, D. (2001). The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med. 7, 569-574.
3. Bennett, A. M., Tang, T. L., Sugimoto, S., Walsh, C. T. and Neel, B. G. (1994). Protein-tyrosine- phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc. Natl. Acad. Sci. USA 91, 7335-7339.
4. Bhattacharya, R., Kwon, J., Wang, E., Mukherjee, P. and Mukhopadhyay, D. (2008a). Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration. J. Mol. Signal. 3, 8.
5. Bhattacharya, R., Sinha, S., Yang, S. P., Patra, C., Dutta, S., Wang, E. and Mukhopadhyay, D. (2008b). The neurotransmitter dopamine modulates vascular permeability in the endothelium. J. Mol. Signal. 3, 14.
6. Carmeliet, P. (2003). Angiogenesis in health and disease. Nat. Med. 9, 653-660.
7. Chakroborty, D., Chowdhury, U. R., Sarkar, C., Baral, R., Dasgupta, P. S. and Basu, S. (2008). Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J. Clin. Invest. 118, 1380-1389.
8. Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R. et al. (2008). Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36, 296-327.
9. Dvorak, H. F. (1990). Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog. Clin. Biol. Res. 354A, 317-330.
10. Dvorak, H. F., Orenstein, N. S., Carvalho, A. C., Churchill, W. H., Dvorak, A. M., Galli, S. J., Feder, J., Bitzer, A. M., Rypysc, J. and Giovinco, P. (1979). Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J. Immunol. 122, 166-174.
11. Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F. and Dvorak, A. M. (1999). Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237, 97-132.
12. Egan, M. F. and Weinberger, D. R. (1997). Neurobiology of schizophrenia. Curr. Opin. Neurobiol. 7, 701-707.
13. Ferrara, N. (1999). Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237, 1-30.
14. Ferrara, N., Gerber, H. P. and LeCouter, J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
15. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
16. Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
17. Gallicchio, M., Mitola, S., Valdembri, D., Fantozzi, R., Varnum, B., Avanzi, G. C. and Bussolino, F. (2005). Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood 105, 1970-1976.
18. Goldstein, M. and Deutch, A. Y. (1992). Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J. 6, 2413-2421.
19. Graybiel, A. M., Hirsch, E. C. and Agid, Y. (1990). The nigrostriatal system in Parkinson's disease. Adv. Neurol. 53, 17-29.
20. Grazia Lampugnani, M., Zanetti, A., Corada, M., Takahashi, T., Balconi, G., Breviario, F., Orsenigo, F., Cattelino, A., Kemler, R., Daniel, T. O. et al. (2003). Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J. Cell Biol. 161, 793-804.
21. Lu, W., Gong, D., Bar-Sagi, D. and Cole, P. A. (2001). Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol. Cell 8, 759-769.
22. Matsumoto, T., Bohman, S., Dixelius, J., Berge, T., Dimberg, A., Magnusson, P., Wang, L., Wikner, C., Qi, J. H., Wernstedt, C. et al. (2005). VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J. 24, 2342-2353.
23. Mitola, S., Brenchio, B., Piccinini, M., Tertoolen, L., Zammataro, L., Breier, G., Rinaudo, M. T., den Hertog, J., Arese, M. and Bussolino, F. (2006). Type I collagen limits VEGFR-2 signaling by a SHP2 protein-tyrosine phosphatase-dependent mechanism 1. Circ. Res. 98, 45-54.
24. Mukhopadhyay, D., Zeng, H. and Bhattacharya, R. (2004). Complexity in the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-receptors signaling. Mol. Cell Biochem. 264, 51-61.
25. Neel, B. G., Gu, H. and Pao, L. (2003). The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28, 284-293.
26. Neve, K. A., Seamans, J. K. and Trantham-Davidson, H. (2004). Dopamine receptor signaling. J. Recept. Signal Transduct. Res. 24, 165-205.
27. Olanow, C. W. and Tatton, W. G. (1999). Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123-144.
28. Olsson, A. K., Dimberg, A., Kreuger, J. and Claesson-Welsh, L. (2006). VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359-371.
29. Risau, W. (1997). Mechanisms of angiogenesis. Nature 386, 671-674.
30. Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N. and Shibuya, M. (2005). Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc. Natl. Acad. Sci. USA 102, 1076-1081.
31. Samayawardhena, L. A., Hu, J., Stein, P. L. and Craig, A. W. (2006). Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor. Cell. Signal. 18, 1447-1454.
32. Sarkar, C., Chakroborty, D., Mitra, R. B., Banerjee, S., Dasgupta, P. S. and Basu, S. (2004). Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 287, H1554-H1560.
33. Sarkar, C., Chakroborty, D., Chowdhury, U. R., Dasgupta, P. S. and Basu, S. (2008). Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin. Cancer Res. 14, 2502-2510.
34. Seo, D. W., Li, H., Guedez, L., Wingfield, P. T., Diaz, T., Salloum, R., Wei, B. Y. and Stetler-Stevenson, W. G. (2003). TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114, 171-180.
35. Shibuya, M. (2006). Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 39, 469-478.
36. Shibuya, M. (2008). Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 41, 278-286.
37. Song, K. S., Scherer, P. E., Tang, Z., Okamoto, T., Li, S., Chafel, M., Chu, C., Kohtz, D. S. and Lisanti, M. P. (1996). Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J. Biol. Chem. 271, 15160-15165.
38. Sueishi, K., Yonemitsu, Y., Nakagawa, K., Kaneda, Y., Kumamoto, M. and Nakashima, Y. (1997). Atherosclerosis and angiogenesis: its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. Ann. NY Acad. Sci. 811, 311-322; 322-324.
39. Takahashi, T., Yamaguchi, S., Chida, K. and Shibuya, M. (2001). A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J. 20, 2768-2778.
40. Tang, H., Zhao, Z. J., Huang, X. Y., Landon, E. J. and Inagami, T. (1999). Fyn kinase-directed activation of SH2 domain-containing protein-tyrosine phosphatase SHP-2 by Gi protein-coupled receptors in Madin-Darby canine kidney cells. J. Biol. Chem. 274, 12401-12407.
41. Vogel, W., Lammers, R., Huang, J. and Ullrich, A. (1993). Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science 259, 1611-1614.
42. Wick, M. M. (1978). Dopamine: a novel antitumor agent active against B-16 melanoma in vivo. J. Invest. Dermatol. 71, 163-164.
43. Wick, M. M. (1979). Levodopa and dopamine analogs: melanin precursors as antitumor agents in experimental human and murine leukemia. Cancer Treat. Rep. 63, 991-997.
44. Zachary, I. (2003). VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. 31, 1171-1177.
45. Zeng, H., Sanyal, S. and Mukhopadhyay, D. (2001). Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J. Biol. Chem. 276, 32714-32719.